.Pharmacolibrary.Drugs.ATC.N.N03AE01

Information

Clonazepam is a benzodiazepine anticonvulsant used primarily for the treatment of epilepsy, panic disorders, and sometimes for movement disorders. It enhances the activity of gamma-aminobutyric acid (GABA) and is approved for use in many countries including the US.

Pharmacokinetics

Pharmacokinetic parameters determined in healthy adult subjects after single oral dose administration.

References

1. Kruizinga, MD, et al., & van Esdonk, MJ (2022). Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations. British journal of clinical pharmacology 88(5) 2236–2245. DOI:10.1111/bcp.15152 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34811788

2. dos Santos, FM, et al., & Noël, F (2009). Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Therapeutic drug monitoring 31(5) 566–574. DOI:10.1097/FTD.0b013e3181b1dd76 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19730280

3. Genis-Najera, L, & Sañudo-Maury, ME (2024). Bioequivalence Study of Two Tablet Formulations of Clonazepam 2 mg: A Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under Fasting Conditions. Neurology and therapy 13(1) 141–152. DOI:10.1007/s40120-023-00567-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38041794

Revisions

• 06/2025 initial generated model